Ascendis Pharma A/S
ASND
Rang in aandelen
#1499
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aandeelprijs
$234.36
Marktkapitalisatie
$14.62B
Verandering (1 dag)
1.92%
Verandering (1 jaar)
14.20%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Categorie
Healthcare
Winst voor Ascendis Pharma A/S (ASND)
Winst in Jun 2026 TTM: $119.93M
Volgens de meest recente financiële verslagen van Ascendis Pharma A/S bedraagt de huidige winst van het bedrijf $119.93M. In 2024 behaalde het bedrijf een winst van $-388.38M, een stijging ten opzichte van de winst van 2023, die $-524.15M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Ascendis Pharma A/S van 2012 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $119.93M | -150.04% |
| 2025 | $-239.65M | -38.30% |
| 2024 | $-388.38M | -25.90% |
| 2023 | $-524.15M | -15.43% |
| 2022 | $-619.81M | 41.96% |
| 2021 | $-436.60M | -14.48% |
| 2020 | $-510.50M | 108.47% |
| 2019 | $-244.87M | 63.30% |
| 2018 | $-149.95M | 0.48% |
| 2017 | $-149.24M | 106.36% |
| 2016 | $-72.32M | 98.38% |
| 2015 | $-36.46M | 191.39% |
| 2014 | $-12.51M | -293.36% |
| 2013 | $6.47M | 281.71% |
| 2012 | $1.70M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 4,298.37% |
US
|
|
| $-3.09B | -2,674.04% |
US
|
|
| $-4.02B | -3,448.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,526.51% |
NL
|
